日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Th17-Immune Response in Patients With Membranous Nephropathy Is Associated With Thrombosis and Relapses

膜性肾病患者的Th17免疫反应与血栓形成和复发相关

Cremoni, Marion; Brglez, Vesna; Perez, Sandra; Decoupigny, Fabrice; Zorzi, Kévin; Andreani, Marine; Gérard, Alexandre; Boyer-Suavet, Sonia; Ruetsch, Caroline; Benzaken, Sylvia; Esnault, Vincent; Seitz-Polski, Barbara

Assessing Prognostic and Predictive Biomarkers of Regorafenib Response in Patients with Advanced Soft Tissue Sarcoma: REGOSARC Study

评估瑞戈非尼治疗晚期软组织肉瘤患者的预后和预测生物标志物:REGOSARC 研究

Brodowicz, Thomas; Liegl-Atzwanger, Bernadette; Penel, Nicolas; Mir, Olivier; Blay, Jean-Yves; Kashofer, Karl; Le Cesne, Axel; Decoupigny, Emilie; Wallet, Jennifer; Hamacher, Rainer; Deley, Marie-Cécile Le

REGOSARC: Regorafenib versus placebo in doxorubicin-refractory soft-tissue sarcoma-A quality-adjusted time without symptoms of progression or toxicity analysis

REGOSARC:瑞戈非尼与安慰剂治疗多柔比星难治性软组织肉瘤——一项质量调整无进展或毒性症状时间分析

Berry, Vincent; Basson, Laurent; Bogart, Emilie; Mir, Olivier; Blay, Jean-Yves; Italiano, Antoine; Bertucci, François; Chevreau, Christine; Clisant-Delaine, Stéphanie; Liegl-Antzager, Bernadette; Tresch-Bruneel, Emmanuelle; Wallet, Jennifer; Taieb, Sophie; Decoupigny, Emilie; Le Cesne, Axel; Brodowicz, Thomas; Penel, Nicolas

Circulating vascular endothelial growth factor (VEGF) as predictive factor of progression-free survival in patients with advanced chordoma receiving sorafenib: an analysis from a phase II trial of the french sarcoma group (GSF/GETO)

循环血管内皮生长因子 (VEGF) 作为索拉非尼治疗晚期脊索瘤患者无进展生存期的预测因子:法国肉瘤组 (GSF/GETO) II 期试验的分析

Lebellec, Loic; Bertucci, François; Tresch-Bruneel, Emmanuelle; Bompas, Emmanuelle; Toiron, Yves; Camoin, Luc; Mir, Olivier; Laurence, Valerie; Clisant, Stephanie; Decoupigny, Emilie; Blay, Jean-Yves; Goncalves, Anthony; Penel, Nicolas